Atypical Sales For Schizophrenics Way Up

A research firm now estimates that sales of atypical antipsychotics for schizophrenics cleared $5 billion in 2005. Actually, since the figures seem to be worldwide numbers, I'd say that's an understatement. Atypical sales in the US alone were expected to hit $10 billion last year--50 percent of that for schizophrenics, 50 percent for bipolars. It'll be interesting to see where the final sales figures wind up.

But, for now, revel in being a target market!